基于[18F]FAPI PET/CT的评分系统用于IgG4相关性疾病患者评估
该回顾性研究纳入85例IgG4相关性疾病患者和10名健康人,建立器官特异性[18F]FAPI PET/CT摄取阈值,并开发FPAS-IgG4评分系统。FPAS-IgG4在活动性疾病组显著高于非活动组(5.2±3.0 vs 1.7±1.3,p<0.0001),以>2为界区分活动性的敏感度93.2%、特异度73.1%。
要点
- 基于健康人器官摄取+3SD建立阈值,[18F]FAPI PET/CT检测IgG4-RD敏感度86.2%、特异度83.3%。
- FPAS-IgG4评分可区分活动与非活动IgG4-RD,阈值>2时敏感度93.2%、特异度73.1%。
- 多因素回归显示FPAS-IgG4与活动性IgG4-RD强相关(p=0.001)。
核心结论
- [18F]FAPI PET/CT可用于监测IgG4-RD活动性并辅助疾病分层。
研究设计与样本
- 回顾性研究纳入85例IgG4-RD患者和10名健康人,均接受[18F]FAPI PET/CT检查。
主要发现
- 85例患者中64处疑似病灶经活检,58处(90.6%)IgG4阳性。
- 基于器官特异性摄取阈值,[18F]FAPI PET/CT检测IgG4-RD的敏感度86.2%、特异度83.3%、准确率85.9%。
- 活动性疾病组FPAS-IgG4高于非活动组(5.2±3.0 vs 1.7±1.3,p<0.0001)。
- FPAS-IgG4>2区分活动与非活动疾病的敏感度93.2%、特异度73.1%。
- 多因素logistic回归显示FPAS-IgG4与活动性IgG4-RD强相关(p=0.001)。
关键数值与推荐
- 器官特异性摄取阈值定义为[18F]FAPI摄取大于健康人相应解剖区域最大标准化摄取值+3SD。
- FPAS-IgG4>2用于区分活动与非活动IgG4-RD,敏感度93.2%、特异度73.1%。
临床怎么用
- 可采用器官特异性摄取阈值解读[18F]FAPI PET/CT以检测IgG4-RD器官受累。
- FPAS-IgG4评分可用于评估疾病活动性,>2提示活动性疾病可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 18F-Fibroblast activation protein inhibitor ([18F]FAPI) positron emission tomography (PET)/CT is an emerging tool for detecting IgG4-related disease (IgG4-RD). However, standardised quantitative analysis and image scoring present ongoing challenges in patients with IgG4-RD. PURPOSE: To establish organ-specific reference thresholds for IgG4-RD involvement on [18F]FAPI PET/CT images, and to develop a novel, clinically applicable scoring system to monitor disease activity in patients with IgG4-RD. METHODS: This retrospective study recruited 85 patients with IgG4-RD and 10 healthy individuals, all of whom underwent [18F]FAPI PET/CT. Organ-specific uptake thresholds were defined as [18F]FAPI uptake greater than the maximal standardised uptake value +3 SD in the corresponding anatomical regions of healthy individuals. Moreover, we developed a novel method, [18F]FAPI PET/CT Activity Score of IgG4-RD (FPAS-IgG4), for scoring disease activity using a logistic regression model with receiver operating characteristics curve analysis. RESULTS: Among 85 patients with IgG4-RD, 64 lesions suspected of IgG4-RD involvement were biopsied and 58 (90.6%) of these lesions were positive for IgG4. [18F]FAPI PET/CT achieved a sensitivity, specificity and accuracy of 86.2%, 83.3% and 85.9%, respectively, for detecting IgG4-RD based on organ-specific uptake thresholds. The active disease group had a higher FPAS-IgG4 than the inactive disease group (5.2±3.0 vs 1.7±1.3, p<0.0001). FPAS-IgG4 >2 showed a sensitivity of 93.2% and a specificity of 73.1% in distinguishing between active and inactive disease. Multivariable logistic regression analysis demonstrated that FPAS-IgG4 was strongly associated with active IgG4-RD (p=0.001). CONCLUSION: [18F]FAPI PET/CT could be a valuable tool for monitoring the activity of IgG4-RD, aiding in disease stratification.
引用
- Chen D, Huang D, Sun C, et al. [18F]FAPI PET/CT-based scoring systems for patient assessment in IgG4-related disease. RMD Open. 2026. PMID: 41781161. doi:10.1136/rmdopen-2025-006540
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。